Cancer heterogeneity—a multifaceted view. (12th July 2013)

• Record Type: Journal Article
• Authors: Melo, Felipe De Sousa E; Vermeulen, Louis; Fessler, Evelyn; Medema, Jan Paul
• Is Part Of: EMBO reports. Volume 14:Number 8(2013)
• Page Start: 686
• Page End: 695
• Publication Date: 2013-07-12
• Subjects: clonal evolution -- cancer stem cells -- cancer subtypes -- therapy resistance; Molecular biology -- Periodicals; Molecular Biology -- Periodicals; Molecular biology; Periodicals; 572.8
• DOI: 10.1038/embor.2013.92
• Languages: English
• ISSNs: 1469-221X

Abstract

Abstract : Cancers of various organs have been categorized into distinct subtypes after increasingly sophisticated taxonomies. Additionally, within a seemingly homogeneous subclass, individual cancers contain diverse tumour cell populations that vary in important cancer‐specific traits such as clonogenicity and invasive potential. Differences that exist between and within a given tumour type have hampered significantly both the proper selection of patients that might benefit from therapy, as well as the development of new targeted agents. In this review, we discuss the differences associated with organ‐specific cancer subtypes and the factors that contribute to intra‐tumour heterogeneity. It is of utmost importance to understand the biological causes that distinguish tumours as well as distinct tumour cell populations within malignancies, as these will ultimately point the way to more rational anti‐cancer treatments. EMBO reports advance online publication 12 July 2013; doi:10.1038/embor.2013.92 Abstract : In this review Jan Paul Medema and colleagues discuss the differences associated with organ‐specific cancer subtypes and the factors that contribute to intra‐tumour heterogeneity. Understanding tumour heterogeneity is crucial for the development of more rational anti‐cancer treatments.